# Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects

> **NCT01913002** · PHASE1 · COMPLETED · sponsor: **Lexicon Pharmaceuticals** · enrollment: 63 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LX4211 800 mg
- **DRUG:** LX4211 2000 mg
- **DRUG:** moxifloxacin 400 mg
- **DRUG:** LX4211 Placebo

## Key facts

- **NCT ID:** NCT01913002
- **Lead sponsor:** Lexicon Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2013-10
- **Final completion:** —
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2013-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01913002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01913002, "Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01913002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*